Heart Failure Management in African Americans: Meeting the Challenge

Heart failure affects 3% of African Americans. The etiology of disease and prognosis for these patients differs substantially from those for non-African Americans. A history of hypertension is associated with development of heart failure more often in African Americans than in non-African Americans and it also appears that target organ involvement is more severe in African Americans with hypertension than in other patient subgroups. Reviewing the results from large-scale clinical end point studies suggests that optimal treatment for heart failure in African Americans may differ from that of their non-African American counterparts. More importantly, concomitant use of beta blockers and angiotensin-converting enzyme inhibitors may be as effective in African Americans as in non-African Americans. Utilizing angiotensin-converting enzyme inhibitors alone may not represent ideal therapy. Of the drugs studied, especially among the beta blockers, carvedilol may be the most effective to use for this population.